The Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and molecular profiles representative of cellular responses to drug perturbations. PANACEA covers a broad spectrum of cellular contexts representative of poor outcome malignancies, including rare ones such as GIST sarcoma and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). PANACEA is uniquely suited to support DREAM Challenges related to the elucidation of drug mechanism of action (MOA), drug sensitivity, and drug synergy.
The goal of this Challenge is to foster development and benchmarking of algorithms to predict the sensitivity, as measured by the area under the dose-response curve, of a cell line to a compound based on the baseline transcriptional profiles of the cell line.
